120 related articles for article (PubMed ID: 35263209)
21. FDA Approval Summary: Selinexor for Relapsed or Refractory Diffuse Large B-Cell Lymphoma.
Kasamon YL; Price LSL; Okusanya OO; Richardson NC; Li RJ; Ma L; Wu YT; Theoret M; Pazdur R; Gormley NJ
Oncologist; 2021 Oct; 26(10):879-886. PubMed ID: 34132444
[TBL] [Abstract][Full Text] [Related]
22. Treatment of acquired drug resistance in multiple myeloma by combination therapy with XPO1 and topoisomerase II inhibitors.
Turner JG; Dawson JL; Grant S; Shain KH; Dalton WS; Dai Y; Meads M; Baz R; Kauffman M; Shacham S; Sullivan DM
J Hematol Oncol; 2016 Aug; 9(1):73. PubMed ID: 27557643
[TBL] [Abstract][Full Text] [Related]
23. [Efficacy of rituximab-containing salvage regimens on relapsed or refractory B-cell non-Hodgkin's lymphoma].
Huang HQ; Bu Q; Xia ZJ; Lin XB; Wang FH; Li YH; Peng YL; Pan ZH; Wang SS; Lin TY; Jiang WQ; Guan ZZ
Ai Zheng; 2006 Apr; 25(4):486-9. PubMed ID: 16613686
[TBL] [Abstract][Full Text] [Related]
24. Safety and activity of selinexor in patients with myelodysplastic syndromes or oligoblastic acute myeloid leukaemia refractory to hypomethylating agents: a single-centre, single-arm, phase 2 trial.
Taylor J; Mi X; Penson AV; Paffenholz SV; Alvarez K; Sigler A; Chung SS; Rampal RK; Park JH; Stein EM; Tallman MS; Sen F; Gönen M; Abdel-Wahab O; Klimek VM
Lancet Haematol; 2020 Aug; 7(8):e566-e574. PubMed ID: 32735836
[TBL] [Abstract][Full Text] [Related]
25. Phase I study of selinexor in combination with dexamethasone, ifosfamide, carboplatin, etoposide chemotherapy in patients with relapsed or refractory peripheral T-cell or natural-killer/T-cell lymphoma.
Tang T; Martin P; Somasundaram N; Lim C; Tao M; Poon E; Yunon MJ; Toh SQ; Yan SX; Farid M; Chan JY; Lim ST
Haematologica; 2021 Dec; 106(12):3170-3175. PubMed ID: 33147935
[TBL] [Abstract][Full Text] [Related]
26. [Efficacy and survival analysis of DICE regimen for 97 patients with relapsed or refractory Non-Hodgkin's lymphoma].
Ping LY; Song YQ; Zheng W; Wang XP; Xie Y; Lin NJ; Tu MF; Ying ZT; Liu WP; Zhang C; Deng LJ; Zhu J
Zhonghua Xue Ye Xue Za Zhi; 2016 Sep; 37(9):790-794. PubMed ID: 27719723
[TBL] [Abstract][Full Text] [Related]
27. Selinexor (KTP-330) - a selective inhibitor of nuclear export (SINE): anti-tumor activity in diffuse large B-cell lymphoma (DLBCL).
Ben-Barouch S; Kuruvilla J
Expert Opin Investig Drugs; 2020 Jan; 29(1):15-21. PubMed ID: 31847605
[No Abstract] [Full Text] [Related]
28. Ifosfamide, idarubicin, and etoposide in relapsed/refractory Hodgkin disease or non-Hodgkin lymphoma: a salvage regimen with high response rates before autologous stem cell transplantation.
Oyan B; Koc Y; Ozdemir E; Kars A; Turker A; Tekuzman G; Kansu E
Biol Blood Marrow Transplant; 2005 Sep; 11(9):688-97. PubMed ID: 16125639
[TBL] [Abstract][Full Text] [Related]
29. [Efficacy of GDP regimen (gemcitabine, dexamethasone, and cisplatin) on relapsed or refractory aggressive non-Hodgkin's Lymphoma: a report of 24 cases].
Fan Y; Huang ZY; Luo LH; Yu HF
Ai Zheng; 2008 Nov; 27(11):1222-5. PubMed ID: 19000458
[TBL] [Abstract][Full Text] [Related]
30. Cladribine combined with rituximab (R-2-CdA) therapy is an effective salvage therapy in relapsed or refractory indolent B-cell non-Hodgkin lymphoma.
Nagai H; Ogura M; Kusumoto S; Takahashi N; Yamaguchi M; Takayama N; Kinoshita T; Motoji T; Ohyashiki K; Kosugi H; Matsuda S; Ohnishi K; Omachi K; Hotta T
Eur J Haematol; 2011 Feb; 86(2):117-23. PubMed ID: 21070370
[TBL] [Abstract][Full Text] [Related]
31. Selinexor plus low-dose bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma.
Bahlis NJ; Sutherland H; White D; Sebag M; Lentzsch S; Kotb R; Venner CP; Gasparetto C; Del Col A; Neri P; Reece D; Kauffman M; Shacham S; Unger TJ; Jeha J; Saint-Martin JR; Shah J; Chen C
Blood; 2018 Dec; 132(24):2546-2554. PubMed ID: 30352784
[TBL] [Abstract][Full Text] [Related]
32. Survival among patients with relapsed/refractory diffuse large B cell lymphoma treated with single-agent selinexor in the SADAL study.
Maerevoet M; Zijlstra JM; Follows G; Casasnovas RO; Vermaat JSP; Kalakonda N; Goy A; Choquet S; Van Den Neste E; Hill B; Thieblemont C; Cavallo F; De la Cruz F; Kuruvilla J; Hamad N; Jaeger U; Caimi P; Gurion R; Warzocha K; Bakhshi S; Sancho JM; Schuster M; Egyed M; Offner F; Vassilakopoulos TP; Samal P; Ku M; Ma X; Corona K; Chamoun K; Shah J; Shacham S; Kauffman MG; Canales M
J Hematol Oncol; 2021 Jul; 14(1):111. PubMed ID: 34271963
[TBL] [Abstract][Full Text] [Related]
33. Comparison of the Effectiveness and Safety of the Oral Selective Inhibitor of Nuclear Export, Selinexor, in Diffuse Large B Cell Lymphoma Subtypes.
Casasnovas RO; Follows G; Zijlstra JM; Vermaat JSP; Kalakonda N; Choquet S; Neste EVD; Hill B; Thieblemont C; Cavallo F; la Cruz F; Kuruvilla J; Hamad N; Jaeger U; Caimi PF; Gurion R; Warzocha K; Bakhshi S; Sancho JM; Schuster M; Egyed M; Offner F; Vassilakopoulos TP; Samal P; Ku M; Ma X; Chamoun K; Shah J; Canales M; Maerevoet M; Shacham S; Kauffman MG; Goy A
Clin Lymphoma Myeloma Leuk; 2022 Jan; 22(1):24-33. PubMed ID: 34493477
[TBL] [Abstract][Full Text] [Related]
34. Oral Selinexor-Dexamethasone for Triple-Class Refractory Multiple Myeloma.
Chari A; Vogl DT; Gavriatopoulou M; Nooka AK; Yee AJ; Huff CA; Moreau P; Dingli D; Cole C; Lonial S; Dimopoulos M; Stewart AK; Richter J; Vij R; Tuchman S; Raab MS; Weisel KC; Delforge M; Cornell RF; Kaminetzky D; Hoffman JE; Costa LJ; Parker TL; Levy M; Schreder M; Meuleman N; Frenzel L; Mohty M; Choquet S; Schiller G; Comenzo RL; Engelhardt M; Illmer T; Vlummens P; Doyen C; Facon T; Karlin L; Perrot A; Podar K; Kauffman MG; Shacham S; Li L; Tang S; Picklesimer C; Saint-Martin JR; Crochiere M; Chang H; Parekh S; Landesman Y; Shah J; Richardson PG; Jagannath S
N Engl J Med; 2019 Aug; 381(8):727-738. PubMed ID: 31433920
[TBL] [Abstract][Full Text] [Related]
35. Selinexor plus low-dose dexamethasone in Chinese patients with relapsed/refractory multiple myeloma previously treated with an immunomodulatory agent and a proteasome inhibitor (MARCH): a phase II, single-arm study.
Qiu L; Xia Z; Fu C; Chen W; Chang C; Fang B; An G; Wei Y; Cai Z; Gao S; Weng J; Chen L; Jing H; Li F; Liu Z; Chen X; Liu J; Wang A; Yu Y; Xiang W; Lynch K; Yu Z; Fu W
BMC Med; 2022 Apr; 20(1):108. PubMed ID: 35379237
[TBL] [Abstract][Full Text] [Related]
36. Repolarization of tumor infiltrating macrophages and increased survival in mouse primary CNS lymphomas after XPO1 and BTK inhibition.
Jiménez I; Carabia J; Bobillo S; Palacio C; Abrisqueta P; Pagès C; Nieto JC; Castellví J; Martínez-Ricarte F; Escoda L; Perla C; Céspedes Torrez DH; Boix J; Purroy N; Puigdefàbregas L; Seoane J; Bosch F; Crespo M
J Neurooncol; 2020 Aug; 149(1):13-25. PubMed ID: 32691208
[TBL] [Abstract][Full Text] [Related]
37. A 2:1 randomized, open-label, phase II study of selinexor vs. physician's choice in older patients with relapsed or refractory acute myeloid leukemia.
Sweet K; Bhatnagar B; Döhner H; Donnellan W; Frankfurt O; Heuser M; Kota V; Liu H; Raffoux E; Roboz GJ; Röllig C; Showel MM; Strickland SA; Vives S; Tang S; Unger TJ; Joshi A; Shen Y; Alvarez MJ; Califano A; Crochiere M; Landesman Y; Kauffman M; Shah J; Shacham S; Savona MR; Montesinos P
Leuk Lymphoma; 2021 Dec; 62(13):3192-3203. PubMed ID: 34323164
[TBL] [Abstract][Full Text] [Related]
38. Lenalidomide plus rituximab can produce durable clinical responses in patients with relapsed or refractory, indolent non-Hodgkin lymphoma.
Tuscano JM; Dutia M; Chee K; Brunson A; Reed-Pease C; Abedi M; Welborn J; O'Donnell RT
Br J Haematol; 2014 May; 165(3):375-81. PubMed ID: 24606326
[TBL] [Abstract][Full Text] [Related]
39. [Bendamustine, vincristine, prednisolone (BOP) in therapy of advanced low-grade non-Hodgkin lymphoma]].
Kath R; Blumenstengel K; Fricke HJ; Peters HD; Höffken K
Dtsch Med Wochenschr; 2001 Feb; 126(8):198-202. PubMed ID: 11256023
[TBL] [Abstract][Full Text] [Related]
40. Salvage chemotherapy with mitoxantrone, fludarabine, cytarabine, and cisplatin (MIFAP) in relapsing and refractory lymphoma.
Hänel M; Kröger N; Kroschinsky F; Birkmann J; Hänel A; Herbst R; Naumann R; Friedrichsen K; Ehninger G; Zander AR; Fiedler F
J Cancer Res Clin Oncol; 2001; 127(6):387-95. PubMed ID: 11414199
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
